Document is current
Any future updates will be listed below
-
Authors
Persson, Karin
Leonardsen, Esten H.
Edwin, Trine Holt
Knapskog, Anne-Brita
Tangen, Gro Gujord
Selbæk, Geir
Wolfers, Thomas
Westlye, Lars T.
Engedal, Knut
-
Funding
Funding for this research was provided by:
The southern and eastern Norway regional health authority (2018078)
The southern and eastern Norway regional health authority (2018078)
University of Oslo (UiO: Life Science Convergence environment (4MENT))
University of Oslo (UiO: Life Science Convergence environment (4MENT))
The Research council of Norway (RCN, 298646)
The Research council of Norway (RCN, 298646)
The European Research Council (802998)
The European Research Council (802998)
- License Information
-
More Information
Article History
Received: 3 May 2023
Accepted: 8 September 2023
First Online: 11 September 2023
Competing interests
: Dr. Persson, Dr. Edwin, and Dr. Knapskog report work with Roche BN29553 trial; Dr. Persson and Dr. Knapskog report work with Novo Nordisk NN6535-4730 trial; Dr. Edwin, and Dr. Knapskog report work with Boehringer-Ingelheim 1346.0023 trial; outside the submitted work. Esten H. Leonardsen is chairman of the board and major shareholder of Biometrical AS. Dr. Selbæk reports participation in a Biogen advisory board. The other authors declare that they have no competing interests.
